Efficacy and safety of camrelizumab plus apatinib in patients with advanced esophageal squamous cell carcinoma previously treated with immune checkpoint inhibitors (CAP 02 Re-challenge): A single-arm, phase II studyXiangrui Meng, Feng Wang, Zhiquan Luo et al.|European Journal of Cancer|2024Cited by 18
Reactivation of mutant p53 in esophageal squamous cell carcinoma by isothiocyanate inhibits tumor growthLulu Guan, Feng Wang|Frontiers in Pharmacology|2023Cited by 6